151 related articles for article (PubMed ID: 37758722)
1. Comprehensive analysis of TLX2 in pan cancer as a prognostic and immunologic biomarker and validation in ovarian cancer.
Chen B; Ding X; Wan A; Qi X; Lin X; Wang H; Mu W; Wang G; Zheng J
Sci Rep; 2023 Sep; 13(1):16244. PubMed ID: 37758722
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of DMRT3 as a Potential Biomarker Associated with the Immune Infiltration in a Pan-Cancer Analysis and Validation in Lung Adenocarcinoma.
Yang D; Liu M; Jiang J; Luo Y; Wang Y; Chen H; Li D; Wang D; Yang Z; Chen H
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551704
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of ZNF692 as a potential biomarker associated with immune infiltration in a pan cancer analysis and validation in hepatocellular carcinoma.
Cai H; Chen S; Wu Z; Wang F; Tang S; Li D; Wang D; Guo W
Aging (Albany NY); 2023 Nov; 15(22):13041-13058. PubMed ID: 37980166
[TBL] [Abstract][Full Text] [Related]
4. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
5. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
6. An Integrative Analysis Revealing ZFHX4-AS1 as a Novel Prognostic Biomarker Correlated with Immune Infiltrates in Ovarian Cancer.
Huang C; Cui H; Lang X; Zhao F
J Immunol Res; 2022; 2022():9912732. PubMed ID: 35795530
[TBL] [Abstract][Full Text] [Related]
7. LBX2-AS1 promotes ovarian cancer progression by facilitating E2F2 gene expression via miR-455-5p and miR-491-5p sponging.
Cao J; Wang H; Liu G; Tang R; Ding Y; Xu P; Wang H; Miao J; Gu X; Han S
J Cell Mol Med; 2021 Jan; 25(2):1178-1189. PubMed ID: 33342041
[TBL] [Abstract][Full Text] [Related]
8. Construction of novel mRNA-miRNA-lncRNA regulatory networks associated with prognosis of ovarian cancer.
Gao L; Li X; Nie X; Guo Q; Liu Q; Qi Y; Liu J; Lin B
J Cancer; 2020; 11(23):7057-7072. PubMed ID: 33123295
[No Abstract] [Full Text] [Related]
9. Pan-Cancer Analysis Based on
Zhang Y; Wang S; Han S; Feng Y
Front Oncol; 2022; 12():844794. PubMed ID: 35359375
[TBL] [Abstract][Full Text] [Related]
10. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
Front Immunol; 2022; 13():943389. PubMed ID: 36003381
[TBL] [Abstract][Full Text] [Related]
11. Histone modification-linked prognostic model for ovarian cancer reveals LBX2 as a novel growth promoter.
Xiong J; Liang H; Sun X; Gao K
J Cell Mol Med; 2024 Apr; 28(8):e18260. PubMed ID: 38520216
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA FAM83H-AS1 acts as a potential oncogenic driver in human ovarian cancer.
Yuan X; Huang Y; Guo M; Hu X; Li P
J Ovarian Res; 2021 Jan; 14(1):6. PubMed ID: 33413565
[TBL] [Abstract][Full Text] [Related]
13. A comprehensively prognostic and immunological analysis of chloride intracellular channel protein 5 (CLIC5) in pan-cancer and identification in ovarian cancer.
Huang Q; Lv Q; Tang W; Pan Y; Xing Y; He M; Wu H; Huang J; Huang C; Lan H; Chen J; Xiao G
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10561-10583. PubMed ID: 37286734
[TBL] [Abstract][Full Text] [Related]
14. NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer.
Dong C; Yin F; Zhu D; Cai X; Chen C; Liu X
J Cell Biochem; 2020 Nov; 121(11):4470-4483. PubMed ID: 32030795
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of PTEN-related ceRNA network revealing the key pathways WDFY3-AS2 - miR-21-5p/miR-221-3p/miR-222-3p - TIMP3 as potential biomarker in tumorigenesis and prognosis of kidney renal clear cell carcinoma.
Zhou X; Liu G; Xu M; Ying X; Li B; Cao F; Cheng S; Xiao B; Cheng M; Liang L; Jia M; Li W; Liu J; Li Z
Mol Carcinog; 2022 May; 61(5):508-523. PubMed ID: 35129856
[TBL] [Abstract][Full Text] [Related]
16. TPD52 is a Potential Prognostic Biomarker and Correlated with Immune Infiltration: A Pan-cancer Analysis.
Miao L; Jing L; Chen B; Zeng T; Chen Y
Curr Mol Med; 2023 Oct; ():. PubMed ID: 38178662
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive landscape of the miRNA-regulated prognostic marker LAYN with immune infiltration and stemness in pan-cancer.
Jiawen W; Jinfu W; Jianyong L; Yaoguang Z; Jianye W
J Cancer Res Clin Oncol; 2023 Oct; 149(13):10989-11011. PubMed ID: 37335337
[TBL] [Abstract][Full Text] [Related]
18. MMP25-AS1/hsa-miR-10a-5p/SERPINE1 axis as a novel prognostic biomarker associated with immune cell infiltration in KIRC.
Tan P; Chen H; Huang Z; Huang M; Du Y; Li T; Chen Z; Liu Y; Fu W
Mol Ther Oncolytics; 2021 Sep; 22():307-325. PubMed ID: 34553021
[TBL] [Abstract][Full Text] [Related]
19. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
Huang S; Sun L; Hou P; Liu K; Wu J
Front Immunol; 2022; 13():944898. PubMed ID: 36148220
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
